Lifecore BiomedicalLFCR -3.23%55 Return-on-Tangible-Equity is 0.00% as of Mar. 2026. GuruFocus rates LFCR with a GF Score™ of 55/100 and a GF Value™ of $6.50 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 898 Drug Manufacturers companies, Lifecore Biomedical ranks worse than 111358.46% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Lifecore Biomedical's annualized net income for the quarter that ended in Mar. 2026 was $-59.92 Mil. Lifecore Biomedical's average shareholder tangible equity for the quarter that ended in Mar. 2026 was $-35.20 Mil. Therefore, Lifecore Biomedical's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was N/A%.
The historical rank and industry rank for Lifecore Biomedical's Return-on-Tangible-Equity or its related term are showing as below:
During the past 13 years, Lifecore Biomedical's highest Return-on-Tangible-Equity was 15.26%. The lowest was -419.82%. And the median was -16.72%.
LFCR's Return-on-Tangible-Equity is not ranked *
in the Drug Manufacturers industry.
Industry Median: 7.88 * Ranked among companies with meaningful Return-on-Tangible-Equity only.
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Lifecore Biomedical Return-on-Tangible-Equity Related Terms
Lifecore Biomedical Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Lifecore Biomedical's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LFCR vs ANIK, DERM, ASRT: Return-on-Tangible-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Lifecore Biomedical's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lifecore Biomedical Return-on-Tangible-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Lifecore Biomedical's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Lifecore Biomedical's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 0.00% mean?
Lifecore Biomedical (LFCR) has a Return-on-Tangible-Equity of 0.00% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Lifecore Biomedical and its competitors. According to the industry distribution chart, Lifecore Biomedical ranks #999999 out of 898 companies in the Drug Manufacturers industry.
Is Lifecore Biomedical's Return-on-Tangible-Equity too high?
Lifecore Biomedical's current Return-on-Tangible-Equity is 0.00%. Based on the distribution chart, Lifecore Biomedical ranks #999999 out of 898 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Lifecore Biomedical has a GF Score™ of 55/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Lifecore Biomedical's Return-on-Tangible-Equity compare to ANIK and DERM?
According to the Drug Manufacturers industry distribution chart, Lifecore Biomedical ranks #999999 out of 898 companies for Return-on-Tangible-Equity. This places Lifecore Biomedical in the lower half of its industry. The industry median Return-on-Tangible-Equity is 7.88. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Drug Manufacturers company?
The median Return-on-Tangible-Equity among Drug Manufacturers companies is 7.88, based on 898 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Lifecore Biomedical and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Equity is 7.88 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lifecore Biomedical's current Return-on-Tangible-Equity is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lifecore Biomedical stock overvalued right now?
Based on GuruFocus' analysis, Lifecore Biomedical (LFCR) is currently considered Modestly Undervalued. The stock's GF Value™ is $6.50, compared to a current price of $5.09 — trading 21.7% below its estimated fair value. The current Return-on-Tangible-Equity is 0.00%. Lifecore Biomedical's overall GF Score™ is 55/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Lifecore Biomedical (LFCR), the current Return-on-Tangible-Equity is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lifecore Biomedical (LFCR) Overvalued in 2026?
Based on GuruFocus' analysis, Lifecore Biomedical stock appears to be undervalued.
The current stock price of $5.09 is trading 21.7% below its estimated GF Value™ of $6.50.
GuruFocus considers Lifecore Biomedical to be Modestly Undervalued.
Key valuation signals for LFCR:
Return-on-Tangible-Equity: 0.00%
GF Value™: $6.50 vs. price of $5.09 (21.7% below fair value)
No single metric tells the full story. See the LFCR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lifecore Biomedical Inc is a fully integrated contract development and manufacturing organization (CDMO) that provides services in the development, fill, and finish of complex sterile injectable pharmaceutical products in syringes, vials, and cartridges. The group recognizes revenue in two different product categories, CDMO and HA manufacturing.
55GF Score
Get the complete analysis for LFCR
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LFCR has been successfully added to your 
